Effects of Gabexate Mesylate on the Gut Microbiota and Metabolomics in Rats with Sepsis

Wenju Sun,Yuqing Cui,Xiaojuan Zhang,Yuze Wang,Zihao Zhang,Xianfei Ding,Huoyan Liang,Dong Wang,Yali Sun,Shaohua Liu,Xiaoguang Duan,Yibin Lu,Tongwen Sun

DOI: https://doi.org/10.2147/jir.s392060

IF: 4.5

2022-12-06

Journal of Inflammation Research

Abstract:Wenju Sun, 1, &ast Yuqing Cui, 1, &ast Xiaojuan Zhang, 1, &ast Yuze Wang, 1 Zihao Zhang, 2 Xianfei Ding, 1 Huoyan Liang, 1 Dong Wang, 1 Yali Sun, 1 Shaohua Liu, 1 Xiaoguang Duan, 1 Yibin Lu, 3 Tongwen Sun 1 1 General ICU, The First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Henan Engineering Research Center for Critical Care Medicine, Zhengzhou, 450052, People's Republic of China; 2 Department of Clinical Medicine, Sanquan College of Xinxiang Medical University, Xinxiang, 453003, People's Republic of China; 3 Department of Critical Care Medicine, Xinyang Hospital Affiliated to Zhengzhou University, Xinyang, 464000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tongwen Sun, General ICU, The First Affiliated Hospital of Zhengzhou University, Henan Key Laboratory of Critical Care Medicine, Zhengzhou Key Laboratory of Sepsis, Henan Engineering Research Center for Critical Care Medicine, Zhengzhou, Henan Province, 450052, People's Republic of China, Email Background: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. However, there is still no single drug that could reduce septic mortality. Previous studies have reported gabexate mesylate (GM) significantly reduced serum inflammatory factors, alleviated sepsis-induced lung injury and improved clinical outcomes. This study aimed to combine with microbiome sequencing and metabolomics analysis to explore the effects of GM administration in septic rats. Methods: Sixty SD rats were randomly divided into the sham control (SC), cecal ligation and puncture (CLP), and GM injection (GM) groups. The mortality was measured and colonic feces were collected to examine the gut microbiota and metabolism 24 h after the procedure. The lung tissues were collected for hematoxylin-eosin staining. Results: We observed the relative abundance of Pygmaiobacter, which contributed to short-chain fatty acids (SCFAs) promotion, Lactobacillus and Erysipelotrichaceae UCG-003 increased in the GM-treated rats, while Escherichia–Shigella and Akkermansia decreased compared to the sepsis-induced lung injury group. Furthermore, these 3 metabolites including Palmitoylethanolamide, Deoxycholic acid and Chenodeoxycholic acid correlated significantly to CLP- and GM-rich genus ( P < 0.05). Besides, the lung tissues of CLP group showed more severe inflammatory infiltration and edema, and the mortality rate in the CLP group (10/20) was significantly higher than in the SC group (0/20) ( P < 0.001) and GM group (4/20) ( P < 0.05). Conclusion: Our findings showed that GM attenuated sepsis-induced lung injury rats and regulated metabolites related to gut microbiota, which may provide an effective treatment for sepsis patients. Keywords: sepsis, gabexate mesylate, gut microbiota, metabolomics, rats Sepsis affects the lives and health of millions of people worldwide annually. Sepsis results in life-threatening organ dysfunction caused by loss of control over infection. 1 One of the main causes of organ failure in sepsis is the inflammatory response due to infection. 2 According to statistical data, the sepsis mortality rate in hospitalized patients is 26.7%, and the sepsis mortality rate in the intensive care unit is 41.9%. 3 Despite recent decades, no treatment has been approved for sepsis other than antibiotics and supportive care. 4 Finding a promising drug to reduce sepsis mortality remains a serious challenge. Gabexate mesylate (GM) is a non-peptidic serine protease inhibitor, 5 which can inhibit the coagulation cascade and be used clinically as an anticoagulant in patients with acute pancreatitis 6 and disseminated intravascular coagulation (DIC). 7 Abnormal coagulation can lead to a large increase in plasma plasminogen activator inhibitor 1 (PAI-1) 8 level, the formation of microthrombi and pulmonary vascular injury. 9 GM can also inhibit various serine proteases produced during inflammation, 10 which has a certain anti-inflammatory effect. It directly inhibited the activation of NF-κB in lipopolysaccharide (LPS)-stimulated macrophages and human monocytes, resulting in decreased production of inflammatory cytokines such as TNF-α, IL-6 and high mobility group protein 1 (HMGB1). 11 Besides, GM has a protective effect in acute lung injury caused by endotoxin, 12 ischemia/reperfusi -Abstract Truncated-

immunology